MPs Urge Wider NHS Access to Weight-Loss Treatments
A parliamentary committee calls for increased availability of obesity drugs and improved services, citing a fragmented and under-resourced system.
Members of Parliament are advocating for greater access to weight-loss medications and comprehensive obesity services within the National Health Service (NHS), arguing that current provisions are inadequate. The committee has criticized the existing system as poorly designed and under-resourced, leading to individuals seeking unlicenced products online due to lack of NHS availability.
Calls for Expanded Access and Services
The MPs recommend a public awareness campaign to highlight the dangers of unlicenced weight-loss drugs purchased online and call for a review of online advertising regulations. They also expressed that current plans to offer the weight-loss drug Mounjaro to only 6% of eligible patients by 2028 are insufficient.
"People can spend their entire lives battling with their weight. We say the NHS should provide effective, structured support to beat obesity for all those who seek it. Instead, those people are repeatedly failed," stated one MP, emphasizing that obesity should be treated with the same seriousness as conditions like diabetes.
Systemic Issues in Obesity Treatment
Jack Doughty of the Obesity Health Alliance echoed these concerns, describing the current treatment system for individuals living with obesity as "fragmented and overstretched." He noted that existing services, encompassing behavioral support, weight-loss medications, and bariatric surgery, are inconsistently available and unequal across the board.
NHS England has indicated that it is exploring ways to expedite the rollout of weight-loss drugs. However, the organization stated that it is currently "rightly prioritising these treatments for those with the most severe and complex needs."